Trials / Completed
CompletedNCT00348686
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Candesartan | 16 mg once daily in oral tablet form |
| DRUG | Candesartan | 32 mg once daily in oral tablet form |
| DRUG | Felodipine | 5 mg once daily in oral tablet form |
| DRUG | Felodipine | 10 mg once daily in oral tablet form |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-07-06
- Last updated
- 2012-04-02
- Results posted
- 2012-04-02
Locations
11 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00348686. Inclusion in this directory is not an endorsement.